Overview

Identifying Actionable Markers to Guide Therapy for Patients With EGFR-Mutant NSCLC

In the Driver’s Seat With EGFR: Application of Mutation Testing to Treatment Selection for NSCLC

Click the"View Activity" button to view this activity.

View Activity

CME/CE is no longer available for this activity

Format

Interactive Practice Guide

Time to Complete

1.25 hr(s).

Release Date

December 30, 2021

Expires On

December 30, 2022

This interactive digital activity combines animated slides and expert video commentary on molecular testing recommendations, guidance on interpreting molecular testing results, and clinical trial evidence to enhance the implementation of precision medicine in the care of patients with EGFR-mutant NSCLC. Through this education, learners explore best practices for EGFR mutation testing, application of clinical trial data to treatment selection, and the role of concurrent mutations in the prognosis and response to therapy of patients with EGFR-mutant NSCLC.

This activity is intended for oncologists and pathologists, and the multidisciplinary care team who care for/manage patients with EGFR-mutant NSCLC.

With over 55% of cancer patients treated by community oncologists, it’s imperative that community oncologists and pathologists apply a dual/multidisciplinary team approach to caring for patients. As precision medicine continues to evolve in cancer care, integration of pathologists within clinical care pathways to interpret test results and offer recommendations for biomarker testing aid in personalized treatment approaches. In this activity, an interactive digital platform with animated slides and expert video commentary on molecular testing recommendations, guidance on interpreting molecular testing results, and clinical trial evidence help clinicians:

• Increase implementation of best practices for EGFR mutation testing in patients with NSCLC

• Apply clinical trial data to treatment selection in patients with EGFR-mutant NSCLC

• Understand the role of concurrent mutations, such as TP53, in the prognosis and response to therapy of patients with EGFR-mutant NSCLC

Upon completion of this activity, participants will be able to:
• Explain best practices for EGFR mutation testing in NSCLC
• Apply current evidence for selection of EGFR TKI therapy across patients with diverse EGFR mutations
• Discuss evidence supporting a role of TP53 in the prognosis of NSCLC and response to therapy
• Interpret recent clinical trial data of therapies for EGFR-mutant NSCLC

This activity is sponsored by the Academy for Continued Healthcare Learning (ACHL).

This activity is supported by an educational grant from Lilly.

Maria E. Arcila, MD
Attending Pathologist and Laboratory Director, Diagnostic Molecular Pathology
Medical Director, Molecular Hematopathology
Memorial Sloan Kettering Cancer Center
New York, NY

Justin Gainor, MD

Director, Center for Thoracic Cancers

Director of Targeted Immunotherapy

Massachusetts General Hospital

Associate Professor of Medicine at Harvard Medical School

Boston, MA

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

The following financial relationships have been provided:

Maria E. Arcila, MD

Consultant: AstraZeneca, Bristol-Myers Squibb, Roche Diagnostics

Speaker’s Agreement: AstraZeneca UK, Ltd., Biocartis Global, Cepheid, Invivioscribe Technologies, Inc., Janssen Global Services, LLC, Merck

Justin Gainor, MD

Consultant/Honorarium: Ariad/Takeda, AstraZeneca, Blueprint, Bristol-Myers Squibb, Genentech, Gilead, GlydeBio, Loxo/Lilly, Merck, Moderna, Oncorus, Pfizer, Novartis, Regeneron

Research Support: Ariad/Takeda, Genentech/Roche, Novartis

Research Support (Institutional): Adaptimmune, Alexo, Array Biopharma, Blueprint, Bristol-Myers Squibb, Jounce, Merck, Moderna, Novartis, Tesaro

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

This activity will take up to 75 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

ABPath MOC credit will be submitted on the first day of each month.

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Pathology’s (ABPath) Maintenance of Certification (MOC) program. This activity offers the following types of credit: Lifelong Learning (Part II).

By providing your ABPath Diplomate number, you consent to have ACHL submit your participation in this activity to the ABPath through the ACCME PARS system.

Completion of this activity, including the pretest, posttest, and follow-up assessments, qualifies as a medium weight MIPS improvement activity under MACRA and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive additional information after completing the activity and receiving your certificate via email.

Laurie Novoryta
lnovoryta@achlcme.org

Overview

Identifying Actionable Markers to Guide Therapy for Patients With EGFR-Mutant NSCLC

Program Description

Intended Audience

Activity Purpose

Learning Objectives

Provider Information

Supporter Information

Faculty

Faculty Disclosure

Staff Disclosure

Disclaimer

Method of Participation

Accreditation and Credit Designation

Program Manager

Related Activities